Dyspepsia workload in urban general practice and implications of the British Society of Gastroenterology Dyspepsia guidelines (1996).

Abstract:

AIM:To define the characteristics of patients consulting with active dyspeptic symptoms in urban general practice, and to consider the implications of applying the British Society of Gastroenterology Dyspepsia management guidelines. DESIGN:Prospective observational study over a period of 12 months. SETTING:Two multipartner, two-centre general practices in the City of Leeds (UK) with a combined target population of 11 011 registered patients. SUBJECTS:A total of 340 patients consulting with active dyspeptic symptoms (52% male; mean age 53 years, range 16-89 years). RESULTS:Of the practice population, 3% consulted with dyspepsia (first-time consulter: 19%; previous consulter not yet investigated: 30%; previously investigated: 51%). Of 168 undiagnosed patients, 43% had upper abdominal pain (dysmotility-like symptoms in 42%), 35% had reflux symptoms, 22% had mixed symptoms, 12% had 'alarm' symptoms and 18% had a history of NSAID use. Patients < 45 years old with simple dyspepsia accounted for 32% of undiagnosed cases. A fifth of the workload was in dealing with undiagnosed dyspeptics over 45 years old. One per cent of the population would require endoscopy if all undiagnosed cases either > 45 years or with complicated dyspepsia were investigated. Of 172 previously investigated patients, 29% had negative tests, 25% had 'minor' findings, and 45% had evidence of acid-peptic disease. Patients with duodenal ulcer disease accounted for 12% of the total workload. CONCLUSIONS:A knowledge of the characteristics of patients consulting with dyspepsia in primary care should allow the adaptation of guidelines, to ensure advice is relevant to local case mix and compatible with local resources.

journal_name

Aliment Pharmacol Ther

authors

Bodger K,Eastwood PG,Manning SI,Daly MJ,Heatley RV

doi

10.1046/j.1365-2036.2000.00728.x

subject

Has Abstract

pub_date

2000-04-01 00:00:00

pages

413-20

issue

4

eissn

0269-2813

issn

1365-2036

pii

apt728

journal_volume

14

pub_type

杂志文章
  • The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.

    abstract:BACKGROUND:Direct antiviral therapies for chronic hepatitis C virus (HCV) infection have expanded treatment options for neglected patient populations, including elderly patients who are ineligible/intolerant to receive interferon (IFN)-based therapy. AIM:To investigate the efficacy, tolerability and potential for drug...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13769

    authors: Vermehren J,Peiffer KH,Welsch C,Grammatikos G,Welker MW,Weiler N,Zeuzem S,Welzel TM,Sarrazin C

    更新日期:2016-10-01 00:00:00

  • Time trends in peptic ulcer, erosive reflux oesophagitis, gastric and oesophageal cancers in a multiracial Asian population.

    abstract:BACKGROUND:Dramatic changes in the prevalence and pattern of gastrointestinal disease has taken place in Asia in recent years. AIM:To compare the prevalence of duodenal (DU) and gastric ulcers (GU), erosive oesophagitis (EO), gastric cancer (GCA) and oesophageal cancer (OCA) and Helicobacter pylori infection over a 10...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.03930.x

    authors: Goh KL,Wong HT,Lim CH,Rosaida MS

    更新日期:2009-04-01 00:00:00

  • Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial.

    abstract:BACKGROUND:Misoprostol is known to be effective in stimulating intestinal transit both in healthy individuals and in patients with chronic constipation when evaluated in short-term trials. The aim of this study was to determine the utility of misoprostol in the long-term management of patients with chronic refractory c...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.1997.00237.x

    authors: Roarty TP,Weber F,Soykan I,McCallum RW

    更新日期:1997-12-01 00:00:00

  • Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers.

    abstract:BACKGROUND:The new tablet formulation of omeprazole (Losec MUPS), is thought to have a stronger acid inhibition than the previously marketed capsules. METHODS:The effects of the proton pump inhibitors lansoprazole and omeprazole tablets on pentagastrin-stimulated acid secretion were compared in Helicobacter pylori-neg...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2000.00823.x

    authors: Müller P,Göksu MA,Fuchs W,Schlüter F,Simon B

    更新日期:2000-09-01 00:00:00

  • Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma.

    abstract:BACKGROUND:Liver transplantation (LT) offers a possible cure for carefully selected patients with hepatocellular carcinoma (HCC). Studies report that preoperative alpha-fetoprotein (AFP) is a prognostic indicator that can predict survival and recurrence in these patients. AIM:To undertake a systematic review of availa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2012.05060.x

    authors: Hakeem AR,Young RS,Marangoni G,Lodge JP,Prasad KR

    更新日期:2012-05-01 00:00:00

  • The use of pictograms improves symptom evaluation by patients with functional dyspepsia.

    abstract:BACKGROUND:No validated patient-reported outcome (PRO) measure exists for functional dyspepsia (FD) assessment. Verbal descriptions of different upper abdominal symptoms may be poorly distinguishable to patients. AIM:To investigate whether understanding of FD symptoms is enhanced by pictograms symbolising the nature o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/apt.12855

    authors: Tack J,Carbone F,Holvoet L,Vanheel H,Vanuytsel T,Vandenberghe A

    更新日期:2014-09-01 00:00:00

  • Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.

    abstract:BACKGROUND:This randomized, double-blind, multicentre study compared lansoprazole with placebo for symptomatic relief of patients with non-erosive gastro-oesophageal reflux disease (GERD). METHODS:214 patients with symptomatic, non-erosive GERD (moderate to severe daytime and/or night-time heartburn greater than half ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1999.00558.x

    authors: Richter JE,Kovacs TO,Greski-Rose PA,Huang section sign B,Fisher R

    更新日期:1999-06-01 00:00:00

  • The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration.

    abstract::Helicobacter pylori produces a 550 kDa, multimeric, nickel-containing urease that catalyses the hydrolysis of urea to yield ammonia and carbonic acid. The ure gene cluster, comprised of seven genes, encodes the two structural subunits UreA (26.5 kDa) and UreB (60.3 kDa), and five accessory proteins: UreI, UreE, UreF, ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1996.22164006.x

    authors: Mobley HL

    更新日期:1996-04-01 00:00:00

  • End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.

    abstract:BACKGROUND:Methotrexate (MTX) is one of the most frequently prescribed drugs in contemporary medicine with a well-recognised hepatotoxic potential, for which stringent laboratory and histological surveillance has long been advocated. AIM:To estimate the population burden of end-stage methotrexate-related liver disease...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12912

    authors: Dawwas MF,Aithal GP

    更新日期:2014-10-01 00:00:00

  • Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome.

    abstract:BACKGROUND:Gut microflora-mucosal interactions may be involved in the pathogenesis of irritable bowel syndrome (IBS). AIM:To investigate the efficacy of a novel prebiotic trans-galactooligosaccharide in changing the colonic microflora and improve the symptoms in IBS sufferers. METHODS:In all, 44 patients with Rome II...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2008.03911.x

    authors: Silk DB,Davis A,Vulevic J,Tzortzis G,Gibson GR

    更新日期:2009-03-01 00:00:00

  • Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.

    abstract:BACKGROUND:Lubiprostone (8 μg b.d.) received US Food and Drug Administration (FDA) approval in 2008 for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in women aged ≥18 years. In 2012, the FDA issued new guidance for IBS-C clinical trials, recommending a composite endpoint incorporating both...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/apt.13807

    authors: Chang L,Chey WD,Drossman D,Losch-Beridon T,Wang M,Lichtlen P,Mareya S

    更新日期:2016-11-01 00:00:00

  • Apoptosis and proliferation in Helicobacter pylori-associated gastric intestinal metaplasia.

    abstract:BACKGROUND:Imbalance between apoptosis and proliferation may be one of the mechanisms underlying H. pylori associated gastric carcinogenesis. AIM:To examine the cell kinetics of gastric intestinal metaplasia and the effect of H. pylori eradication. METHODS:Endoscopic gastric biopsies were obtained from 100 H. pylori-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2001.01057.x

    authors: Leung WK,Yu J,To KF,Go MY,Ma PK,Chan FK,Sung JJ

    更新日期:2001-09-01 00:00:00

  • The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C.

    abstract:BACKGROUND:Studies have shown that past alcohol consumption reduces response rates in patients with chronic hepatitis C treated with interferon monotherapy. AIM:To clarify the importance of alcohol consumption on response rates in patients undergoing treatment with pegylated interferon and ribavirin. METHODS:In a sin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2005.02631.x

    authors: Chang A,Skole K,Gautam M,Schmutz J,Black M,Thomas R,Horwitz B,Friedenberg FK

    更新日期:2005-10-15 00:00:00

  • Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea.

    abstract:BACKGROUND:Irritable bowel syndrome is a widespread disorder with a marked socioeconomic burden. Previous studies support the proposal that a subset of patients with features compatible with diarrhoea-predominant IBS (IBS-D) have bile acid malabsorption (BAM). AIM:To perform a systematic review and meta-analysis to as...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/apt.13227

    authors: Slattery SA,Niaz O,Aziz Q,Ford AC,Farmer AD

    更新日期:2015-07-01 00:00:00

  • Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients.

    abstract:BACKGROUND:Chronic hepatitis C (HCV) treatment with pegylated-interferon (PEG-IFN)/ribavirin (RBV) is often limited by preexisting medical, psychiatric and psychosocial contraindications. However, limited data exist in general patient populations. AIM:To evaluate the percentage of HCV-infected patients in the general ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12200

    authors: Talal AH,LaFleur J,Hoop R,Pandya P,Martin P,Jacobson I,Han J,Korner EJ

    更新日期:2013-02-01 00:00:00

  • Antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in patients with obstructive jaundice: is it worth the cost?

    abstract:BACKGROUND:There are few published data concerning the economic impact of antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in the setting of biliary obstruction. AIM:To perform decision analysis to determine the costs of prophylaxis in patients undergoing endoscopic retrograde cholangiopa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2002.01209.x

    authors: Thompson BF,Arguedas MR,Wilcox CM

    更新日期:2002-04-01 00:00:00

  • Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study.

    abstract:BACKGROUND:Peptic ulcer bleeding remains a major healthcare problem despite decreasing prevalence of peptic ulcer disease. The role of chronic obstructive pulmonary disease (COPD) in the risk of peptic ulcer bleeding has not yet been established. AIM:To determine if COPD patients have a higher risk of peptic ulcer ble...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2012.05028.x

    authors: Huang KW,Luo JC,Leu HB,Lin HC,Lee FY,Chan WL,Lin SJ,Chen JW,Chang FY

    更新日期:2012-04-01 00:00:00

  • Mucosal penetration and clearance of gluten and milk antigens in eosinophilic oesophagitis.

    abstract:BACKGROUND:The Th2 allergic pathway in eosinophilic oesophagitis (EoE) responds to food antigen exposure. AIM:To compare the presence and temporal pattern of food antigen penetration in oesophageal mucosa in active and inactive EoE and controls METHODS: Thirty-two patients with EoE (20 active) and 10 controls were ask...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16180

    authors: Ravi A,Marietta EV,Alexander JA,Peterson K,Lavey C,Geno DM,Murray JA,Katzka DA

    更新日期:2021-02-01 00:00:00

  • Review article: functional dyspepsia--should treatment be targeted on disturbed physiology?

    abstract::In patients who present with chronic unexplained upper abdominal pain or discomfort (functional dyspepsia), therapy should ideally be targeted on correcting the individual's disturbed pathophysiology. Here, putative mechanisms implicated in functional dyspepsia and potential approaches to therapy are critically review...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1995.tb00359.x

    authors: Talley NJ

    更新日期:1995-04-01 00:00:00

  • One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study.

    abstract:BACKGROUND:While empiric acid-suppressive therapy for uninvestigated dyspepsia patients with symptoms of epigastric pain or burning is standard practice, it is unknown whether an early response to therapy predicts outcome. AIM:To evaluate whether a 1-w acid suppression trial is effective for predicting 8-w response in...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2007.03409.x

    authors: van Zanten SV,Flook N,Talley NJ,Vakil N,Lauritsen K,Bolling-Sternevald E,Persson T,Björck E,Svedberg LE,STARS II Study Group.

    更新日期:2007-09-01 00:00:00

  • Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients.

    abstract:BACKGROUND:Optimal management approach is not well defined for subjects who fail initial first- and second-line Helicobacter pylori eradication attempts and are dealt on a case-by-case basis by the specialists. AIM:To evaluate the efficacy and safety of standard and 'rescue' eradication therapies at primary and second...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.02210.x

    authors: Qasim A,Sebastian S,Thornton O,Dobson M,McLoughlin R,Buckley M,O'Connor H,O'Morain C

    更新日期:2005-01-01 00:00:00

  • The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C.

    abstract:BACKGROUND:Intrahepatic non-hypervascular hypointense nodules (NHHNs) detected during the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) have the potential to transition into typical hypervascular hepatocellular carcinoma (HCC). However, ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15490

    authors: Toyoda H,Tada T,Yasuda S,Mizuno K,Sone Y,Kaneoka Y,Maeda A,Akita T,Tanaka J,Kumada T

    更新日期:2019-12-01 00:00:00

  • Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.

    abstract:BACKGROUND:Strong suppression of viral replication and normalization of alanine aminotransferase is feasible with nucleos(t)ide analogues. It is estimated viral replication and liver inflammation can be controlled in 90% of patients with chronic hepatitis B with the current available treatments. AIM:To review the stud...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2007.03481.x

    authors: Leemans WF,Ter Borg MJ,de Man RA

    更新日期:2007-12-01 00:00:00

  • Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease.

    abstract::Unfractioned heparin was recently reported to be beneficial in the treatment of inflammatory bowel disease. The available uncontrolled data show that it may be effective in steroid-resistant ulcerative colitis with a percentage of complete clinical remission of over 70% after an average of 4-6 weeks of therapy. The ad...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2000.00860.x

    authors: Papa A,Danese S,Gasbarrini A,Gasbarrini G

    更新日期:2000-11-01 00:00:00

  • A non-toxic analogue of a coeliac-activating gliadin peptide: a basis for immunomodulation?

    abstract:BACKGROUND:A-gliadin residues 31-49 (peptide A) binds to HLA-DQ2 and is toxic to coeliac small bowel. Analogues of this peptide, which bind to DQ2 molecules but are non-toxic, may be a potential route to inducing tolerance to gliadin in patients with coeliac disease. METHODS:Toxicity was investigated with small bowel ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00512.x

    authors: Biagi F,Ellis HJ,Parnell ND,Shidrawi RG,Thomas PD,O'Reilly N,Corazza GR,Ciclitira PJ

    更新日期:1999-07-01 00:00:00

  • Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

    abstract:BACKGROUND:Psychiatric side-effects may require dose reduction or premature discontinuation of interferon therapy in chronic hepatitis C. New strategies are needed in order to prevent the premature termination of interferon therapy. AIM:To evaluate prospectively the efficacy and tolerability of antidepressant therapy ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2002.01265.x

    authors: Kraus MR,Schäfer A,Faller H,Csef H,Scheurlen M

    更新日期:2002-06-01 00:00:00

  • Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.

    abstract:BACKGROUND:Five oral nucleos(t)ide analogues are available to treat chronic hepatitis B (CHB). With the availability of newer agents, their efficacy on incidence of hepatocellular carcinoma (HCC) is not well described. AIM:To determine the efficacy of oral anti-viral agents in reducing HCC risk in relationship with ot...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.12344

    authors: Singal AK,Salameh H,Kuo YF,Fontana RJ

    更新日期:2013-07-01 00:00:00

  • Potential role of the cannabinoid receptor CB in the pathogenesis of erosive and non-erosive gastro-oesophageal reflux disease.

    abstract:BACKGROUND:Cannabinoid (CB) receptors have been located in brain areas involved in the triggering of TLESRs as well as in the nodose ganglion from which vagal afferents emanate. The distribution of CB(1) receptors has been investigated in the human gastrointestinal mucosa, as expression of inflammatory process. AIM:To...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2010.04377.x

    authors: Calabrese C,Spisni E,Liguori G,Lazzarini G,Valerii MC,Strillacci A,Gionchetti P,Pagotto U,Campieri M,Rizzello F

    更新日期:2010-08-01 00:00:00

  • Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.

    abstract:BACKGROUND:The epidemiology and pathophysiology of non-erosive gastro-oesophageal reflux disease differs from erosive gastro-oesophageal reflux disease. There is a possibility that non-erosive gastro-oesophageal reflux disease treatment requires a different regimen/approach but it is not yet acknowledged. AIM:To inves...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2005.02467.x

    authors: Wada T,Sasaki M,Kataoka H,Tanida S,Itoh K,Ogasawara N,Oshima T,Togawa S,Kubota E,Yamada T,Mori Y,Fujita F,Ohara H,Nakao H,Sobue S,Joh T,Itoh M

    更新日期:2005-06-01 00:00:00

  • A novel diagnostic tool for detecting oesophageal pathology: the PillCam oesophageal video capsule.

    abstract:BACKGROUND:Gastro-oesophageal reflux disease is a common entity. Erosive oesophagitis, ulcers and Barrett's oesophagus, which is found in up to 10% of gastro-oesophageal reflux disease patients, characterize severe gastro-oesophageal reflux disease. Patients with Barrett's oesophagus have 0.5% per patient-year risk of ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.02206.x

    authors: Eliakim R,Yassin K,Shlomi I,Suissa A,Eisen GM

    更新日期:2004-11-15 00:00:00